Arbaclofen placarbil ( , also known as XP19986) is a
prodrug of ''R''-
baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with
GERD and spasticity due to
multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in
phase III clinical trials.
It is being developed as an addiction medicine to treat alcoholism. It is also studied as a potential therapeutic for some autistic subjects.
[ ]
See also
*
Gabapentin enacarbil
Gabapentin enacarbil (Horizant () (), Regnite (in Japan)) is an anticonvulsant and analgesic drug of the gabapentinoid class, and a prodrug to gabapentin. It was designed for increased oral bioavailability over gabapentin, and human trials s ...
*
Lesogaberan
Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to ...
References
Abandoned drugs
Amino acids
Calcium channel blockers
Chloroarenes
GABA analogues
GABAB receptor agonists
Prodrugs
{{musculoskeletal-drug-stub